Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) EBITDA (2016 - 2026)

Wave Life Sciences (WVE) has disclosed EBITDA for 12 consecutive years, with -$26.1 million as the latest value for Q1 2026.

  • For Q1 2026, EBITDA rose 44.27% year-over-year to -$26.1 million; the TTM value through Mar 2026 reached -$183.6 million, down 63.47%, while the annual FY2025 figure was -$204.4 million, 110.37% down from the prior year.
  • EBITDA hit -$26.1 million in Q1 2026 for Wave Life Sciences, up from -$53.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $29.2 million in Q4 2024 and bottomed at -$61.7 million in Q3 2024.
  • Average EBITDA over 5 years is -$32.2 million, with a median of -$37.9 million recorded in 2022.
  • On a YoY basis, EBITDA climbed as much as 279.96% in 2024 and fell as far as 954.02% in 2024.
  • Wave Life Sciences' EBITDA stood at -$43.6 million in 2022, then surged by 62.86% to -$16.2 million in 2023, then skyrocketed by 279.96% to $29.2 million in 2024, then tumbled by 282.64% to -$53.2 million in 2025, then skyrocketed by 50.99% to -$26.1 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$26.1 million, -$53.2 million, and -$53.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.